Ottawa: Canada’s drug regulator announced that it has authorized the Pfizer-BioNTech Comirnaty Covid-19 vaccine for use as a booster dose in children aged 5 to 11 years. Health Canada said the booster dose provides an excellent option to restore protection for this age group, particularly those at risk of serious illness, news agency Xinhua reported.Also Read – Covid-19: Scientists find master key to fight all strains You need to know
Meanwhile, the National Advisory Committee on Immunization (NACI) on Friday released national guidelines for its use.
NACI recommends that children aged 5 to 11 years who have an underlying medical condition that puts them at high risk of severe illness due to Covid-19, including immunocompromised children, should be offered a first booster dose of 10 mcg vaccine. . At least six months after completion of primary series.
For all other children in this age group, NACI recommends that the 10 mcg Comirnaty vaccine may be offered as the first booster at least six months after completion of the primary series in the context of the highest epidemiological risk.
